Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study

Ruamviboonsuk, Paisan; Tadarati, Mongkol; Vanichvaranont, Sumeth; Hanutsaha, Prut; Pokawattana, Nattapol

doi:10.1136/bjo.2009.173120

Cited by 56 publications

(36 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reports of greater expression of VEGF in histopathology and increased VEGF in the aqueous humor have suggested the association of PCV and VEGF [16,17]. Some of the reports present that the anti-VEGF treatment might be a potential treatment to improve PCV [19,20,21,22,23,24,27]. Conversely, in terms of the polyp regression rate, anti-VEGF monotherapy could be inferior to PDT monotherapy or intravitreal anti-VEGF treatment combined with PDT [19,27].…”

Section: Discussionmentioning

confidence: 99%

“…Some of the reports present that the anti-VEGF treatment might be a potential treatment to improve PCV [19,20,21,22,23,24,27]. Conversely, in terms of the polyp regression rate, anti-VEGF monotherapy could be inferior to PDT monotherapy or intravitreal anti-VEGF treatment combined with PDT [19,27]. The previous study indicated that eyes with a cluster of grapes-like polypoidal dilatations of the vessels had a high risk for severe visual loss [5].…”

Section: Discussionmentioning

confidence: 99%

“…The previous studies have shown that 88–100% of polypoidal lesions showed regression after intravitreal ranibizumab injection combined with PDT [27,28]. One reason for the percentile gap of polyp regression in previous studies could be the different treatment protocols.…”

Section: Discussionmentioning

confidence: 99%

“…In our study, the patients in group 1 received 1 session of PDT and 1 intravitreal injection of 0.5 mg of ranibizumab followed by reinjection of ranibizumab, and were injected on an as-needed basis guided by OCT, FA and ICGA. During the prior published studies, the patients received 1 session of PDT and 3 injections of ranibizumab on a monthly basis [27,28]. During the follow-up period, in case polyps were identified by ICGA, patients received an additional session of PDT [27].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

One-Year Results of Intravitreal Ranibizumab with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

2011

View full text Add to dashboard Cite

Purpose: To evaluate the safety and efficacy of intravitreal ranibizumab with or without photodynamic therapy (PDT) in the treatment of polypoidal choroidal vasculopathy (PCV) in Korean patients. Methods: A retrospective chart review of 22 patients (24 eyes) with PCV was conducted. Nine eyes were treated with intravitreal ranibizumab combined with a single session of PDT (group 1), and 15 eyes were treated only with ranibizumab (group 2). Such clinical evaluations as best-corrected Snellen visual acuity, central retinal thickness (CRT) by optical coherence tomography (OCT), fluorescein angiography (FA) and indocyanine green angiography (ICGA) were done at baseline, 1, 3, 6, 9 and 12 months after the first injections. Ranibizumab was reinjected on an as-needed basis guided by OCT, FA and ICGA, or at the doctor’s discretion. Results: The mean follow-up duration was 22.5 months (range 12–37). The mean best-corrected visual acuity (logMAR) improved, and the mean CRT decreased throughout 12 months in both groups; no statistically significant difference between the groups was found (p = 0.327, p = 0.073, respectively). The number of ranibizumab injections was not significantly different either (p = 0.555). Conclusions: Intravitreal ranibizumab with or without PDT for PCV in Korean patients resulted in visual and anatomical improvement over the 1-year follow-up period.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

One-Year Results of Intravitreal Ranibizumab with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

2011

View full text Add to dashboard Cite

show abstract

“…Although combined therapy with PDT and anti-VEGF agents has been reported in patients with neovascular age-related macular degeneration [25,26,27,28,29], there are few reports of combination therapy for PCV [30,31]. The purpose of the present study was to evaluate the results of combination therapy with PDT and intravitreal anti-VEGF injection in PCV patients.…”

Section: Introductionmentioning

confidence: 99%

Photodynamic Therapy Combined with Intravitreal Injection of Vascular Endothelial Growth Factor Antibody for Polypoidal Choroidal Vasculopathy

Moon

Kim

et al. 2011

Ophthalmologica

View full text Add to dashboard Cite

Background/Aims: To evaluate the efficacy of photodynamic therapy (PDT) combined with intravitreal injection of anti-vascular-endothelial-growth-factor (anti-VEGF) antibody in patients with polypoidal choroidal vasculopathy (PCV). Methods: Twenty-two eyes of 22 patients with PCV followed for 12 months after combination therapy with PDT and anti-VEGF were retrospectively reviewed. Patients received intravitreal anti-VEGF (1.25 mg bevacizumab or 0.5 mg ranibizumab) within 7 days after PDT. Retreatment with PDT and intravitreal anti-VEGF injections, or with intravitreal anti-VEGF alone, was performed when indicated. The main outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT). Results: Mean logMAR BCVA was 0.43 at baseline and 0.45, 0.36, 0.30 and 0.28 at 1, 3, 6 and 12 months, respectively, after the initial combination therapy. Mean BCVA was significantly improved at 6 and 12 months after treatment (p < 0.05). Mean CFT was 269.4 µm at baseline and 180.1, 136.7, 127.5 and 139.6 µm at 1, 3, 6 and 12 months, respectively, after the initial combination therapy. CFT decreased significantly throughout the follow-up period. At 12 months, mean BCVA improved by 1.5 lines, and mean CFT decreased by 129.8 µm. Polypoidal lesions disappeared in 7 of the 13 eyes in which indocyanine green angiography was performed at 12 months. No changes in the branching vascular network were observed in any of these 13 eyes. Patients were treated with PDT a mean of 1.3 times and injected with intravitreal anti-VEGF a mean of 3.4 times over the 12-month period. Conclusion: Combined PDT and intravitreal anti-VEGF may improve visual acuity and decrease CFT at 12 months. Large long-term prospective studies are needed to evaluate the efficacy and safety of combination therapy.

show abstract

Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy

et al. 2020

View full text Add to dashboard Cite

trial showed that for patients with polypoidal choroidal vasculopathy (PCV), intravitreal ranibizumab in combination with verteporfin photodynamic therapy improves visual acuity relative to ranibizumab monotherapy. However, whether combination therapy is incrementally cost-effective relative to monotherapy during a lifetime is unclear.OBJECTIVE To assess the incremental cost-effectiveness of combination therapy compared with ranibizumab monotherapy in patients with PCV. DESIGN, SETTING, AND PARTICIPANTSThis model-based, economic evaluation used 2018 unit cost data from a tertiary eye hospital in Singapore, first-and second-year outcomes and resource use data from a multicenter trial across various Asian countries (EVEREST II) to model a hypothetical cohort of patients with symptomatic PCV. Scenario analyses and deterministic and probabilistic sensitivity analyses were performed to examine uncertainty.

show abstract

Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study

Cited by 56 publications

References 25 publications

One-Year Results of Intravitreal Ranibizumab with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

One-Year Results of Intravitreal Ranibizumab with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

Photodynamic Therapy Combined with Intravitreal Injection of Vascular Endothelial Growth Factor Antibody for Polypoidal Choroidal Vasculopathy

Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy

Contact Info

Product

Resources

About